If you recall in November last year Tony completely forgot to...

If you recall in November last year Tony completely forgot to file the 4C.

My point being, no one at FOD knows anything about Investor Relations and in my opinion, they will for the umpteenth time botch the release failing to highlight the important data.

It will be key that they break down the sales between OBL and the shots to see where the growth drivers and operational leverage are in the business. The Shots should be a high margin business so that should significantly improve valuation multiples etc if they are able to demonstrate that. My assumption is that there will once again be very minimal Eridani sales so we can simply strip them out.

A big reminder that there won't be any sanitiser sales to inflate the revenue figures this year. So if they didn't PCP the corresponding business units then the annual results will look pretty average